| HOME >> MEDICINE >> TECHNOLOGY |
5,8493,0223,0213,02114,913Adjusted gross profit
$
35,418$
31,252$
33,371$
40,217$
40,258Adjusted gross profit %
29.5%24.4%28.4%29.7%28.0%Reported operating expenses
$
22,328$
23,677$
28,505$
25,387$
99,897Deal-related amortization(1)
(3,615)(3,615)(3,616)(3,615)(14,461)Restructuring charges
--(7,081)(1,674)(8,755)Adjusted operating expenses
$
8,713$
20,062$
7,808$
20,098$
76,681Adjusted operating expenses %
15.6%15.7%15.1%14.9%15.3%Reported operating income
$
7,241$
4,553$
,845$
,809$
25,448Deal-related amortization(1)
9,4646,6376,6376,63629,374Restructuring charges
--7,0811,6748,755Adjusted operating income
$
,705$
,190$
5,563$
20,119$
3,577Adjusted operating income %
13.9%8.7%13.2%14.9%12.7%Rx PharmaceuticalsNet sales
$
27,627$
77,196$
55,591$
56,975$
7,389Reported gross profit
$
41,460$
91,380$
83,331$
72,450$
288,621Deal-related amortization(1)
7,3537,9698,5748,53232,428Inventory step-up
27,179---27,179Adjusted gross profit
$
75,992$
99,349$
91,905$
80,982$
348,228Adjusted gross profit %
59.5%56.1%59.1%51.6%56.4%Reported operating expenses
$
,975$
21,404$
,076$
20,671$
75,126Acquisition-related costs
(3,156)(599)--(3,755)Earnings associated with sale of IPR&D projects
3,500---3,500Write-off of in-process R&D
---(750)(750)Adjusted operating expenses
$
7,319$
20,805$
,076$
9,921$
74,121Adjusted operating expenses %
13.6%11.7%10.3%12.7%12.0%Reported operating income
$
24,485$
9,976$
7,255$
51,779$
213,495Deal-related amortization(1)
7,3537,969
'/>"/>
| SOURCE Perrigo Company Copyright©2012 PR Newswire. All rights reserved |